Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP519445.RABSxrI8VVuGYta8gMcur2Lx-r7PQ4rhYVKpQ47c0Uzl8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP519445.RABSxrI8VVuGYta8gMcur2Lx-r7PQ4rhYVKpQ47c0Uzl8130_assertion type Assertion NP519445.RABSxrI8VVuGYta8gMcur2Lx-r7PQ4rhYVKpQ47c0Uzl8130_head.
- NP519445.RABSxrI8VVuGYta8gMcur2Lx-r7PQ4rhYVKpQ47c0Uzl8130_assertion description "[Furthermore, patients affected by essential thrombocythemia who are carriers of the Janus kinase 2 Val617Phe mutation show a higher incidence of venous thromboembolism both before, and at the time of diagnosis, compared with noncarriers, and recent evidence of splanchnic and cerebral vein thrombosis in carriers of the Janus kinase 2 Val617Phe mutation has been reported.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP519445.RABSxrI8VVuGYta8gMcur2Lx-r7PQ4rhYVKpQ47c0Uzl8130_provenance.
- NP519445.RABSxrI8VVuGYta8gMcur2Lx-r7PQ4rhYVKpQ47c0Uzl8130_assertion evidence source_evidence_literature NP519445.RABSxrI8VVuGYta8gMcur2Lx-r7PQ4rhYVKpQ47c0Uzl8130_provenance.
- NP519445.RABSxrI8VVuGYta8gMcur2Lx-r7PQ4rhYVKpQ47c0Uzl8130_assertion SIO_000772 18600099 NP519445.RABSxrI8VVuGYta8gMcur2Lx-r7PQ4rhYVKpQ47c0Uzl8130_provenance.
- NP519445.RABSxrI8VVuGYta8gMcur2Lx-r7PQ4rhYVKpQ47c0Uzl8130_assertion wasDerivedFrom befree-20150227 NP519445.RABSxrI8VVuGYta8gMcur2Lx-r7PQ4rhYVKpQ47c0Uzl8130_provenance.
- NP519445.RABSxrI8VVuGYta8gMcur2Lx-r7PQ4rhYVKpQ47c0Uzl8130_assertion wasGeneratedBy ECO_0000203 NP519445.RABSxrI8VVuGYta8gMcur2Lx-r7PQ4rhYVKpQ47c0Uzl8130_provenance.